Original Article

Acta Diabetologica

, Volume 47, Issue 2, pp 119-124

First online:

Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus

  • Peter KubiszAffiliated withNational Center of Hemostasis and Thrombosis, Jessenius Faculty of Medicine, Comenius University Email author 
  • , Peter ChudýAffiliated withNational Center of Hemostasis and Thrombosis, Jessenius Faculty of Medicine, Comenius University
  • , Ján StaškoAffiliated withNational Center of Hemostasis and Thrombosis, Jessenius Faculty of Medicine, Comenius University
  • , Peter GalajdaAffiliated withClinic of Internal Medicine 1, Jessenius Faculty of Medicine, Comenius University
  • , Pavol HollýAffiliated withNational Center of Hemostasis and Thrombosis, Jessenius Faculty of Medicine, Comenius University
  • , Robert VyšehradskýAffiliated withClinic of Pneumophthisiology, Jessenius Faculty of Medicine, Comenius University
  • , Marián MokáňAffiliated withClinic of Internal Medicine 1, Jessenius Faculty of Medicine, Comenius University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Relationship between serum vascular endothelial growth factor (VEGF) level and parameters of endothelial injury and/or dysfunction in patients with diabetes mellitus type 2 with or without microalbuminuria was investigated. Eighty-four diabetic patients were divided in two subgroups (42 each): normoalbuminuric (NAU) and microalbuminuric (MAU). Forty-two blood donors were in control group. Serum VEGF and plasma von Willebrand factor, soluble thrombomodulin, plasminogen activator inhibitor 1, thrombin-activatable fibrinolysis inhibitor (TAFI) and tissue plasminogen activator (t-PA) were measured using enzyme-linked immunosorbent assay in all subjects. VEGF was significantly higher in NAU compared to controls. The difference between MAU and controls was not statistically significant, but there was a trend toward significance. Only TAFI correlated with VEGF in MAU. An observed significant increase of serum VEGF level already in NAU suggests that serum VEGF could be a sensitive predictor of endothelial dysfunction in type 2 diabetes.

Keywords

VEGF Diabetes mellitus type 2 Endothelial dysfunction